“Outliers are what you’re going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company’s AI-driven drug development strategy.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
“Outliers are what you’re going for,” Model Medicines CEO Daniel Haders, Ph.D., told Fierce to explain the company’s AI-driven drug development strategy.